Last updated: February 23, 2026
What is NDC 45802-0088?
NDC 45802-0088 refers to a specific drug product listed in the National Drug Code (NDC) system. The code corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy indicated for the treatment of spinal muscular atrophy (SMA) in pediatric patients under 2 years of age.
Current Market Overview
Zolgensma is the most expensive single-dose gene therapy approved by the FDA. Its price is set at roughly $2.1 million per treatment (as of 2022), making it a unique product in the rare disease space with high stakes for market penetration, reimbursement, and competition.
Production and Regulatory Status
- FDA Approval: May 24, 2019
- EMA Approval: May 2020
- Manufacturing: Biogen in partnership with Novartis/Spark Therapeutics
- Indications: SMA in patients under 2 years old, including presymptomatic cases
Market Size and Demand Drivers
Patient Population
- SMA Type 1 incidence: approximately 1 in 10,000 live births
- Estimated number of eligible infants in the U.S.: ~350 annually
- Global SMA population for this indication: roughly 600-700 per year, with potential expansion to older patients in subsequent approvals
Treatment Adoption
- Prevailing treatment options: supportive care, nusinersen (Spinraza), and risdiplam (Evrysdi)
- Zolgensma's unique one-time administration offers advantages for early intervention, leading to early adoption in genetic newborn screening programs
Market Penetration
- Early adoption in U.S. and European markets
- Surge in newborn screening for SMA in the U.S. increased early diagnosis and treatment rates
- Insurance coverage and high prices remain barriers but are often mitigated by value-based contracts
Competitive Landscape
| Product |
Type |
Price (per dose) |
Approval Year |
Key Features |
| Zolgensma |
Gene Therapy |
~$2.1 million |
2019 |
Single-dose, high efficacy in infants |
| Spinraza (nusinersen) |
Antisense oligonucleotide |
~$750,000 per year |
2016 |
Multiple doses, ongoing treatment |
| Evrysdi (risdiplam) |
Oral SMN2 splicing modifier |
~$340,000/year |
2020 |
Oral delivery, similar efficacy |
Market Share
- Zolgensma dominates for infants diagnosed early
- Nusinersen remains used, especially for older children
- Competition increasingly driven by evolving protocols and reimbursement strategies
Price Projections and Market Dynamics
Short-Term Outlook (Next 1-2 Years)
- Revenue Potential: $3-4 billion annually, assuming steady uptake
- Pricing Stability: Price likely to remain near $2.1 million, barring policy or reimbursement shifts
- Reimbursement Risks: Payer negotiations and outcome-based contracts influence net price
Medium- to Long-Term Trends (3-5 Years)
- Price Adjustment: Slight reductions possible for new formulations or biosimilars, if approved
- Market Expansion: Potential approval for older SMA patients could increase patient pool by 20-50%
- Cost-Effectiveness Models: Growing reliance on health economic assessments may pressure prices downward
Key Factors Affecting Price and Market Growth
- Regulatory Approvals: Expanded age indications, new formulations
- Cost-Containment Policies: Payer pressure to control high-cost therapies
- Manufacturing Efficiency: Advances may reduce production costs, impacting pricing
- Competition: Entry of biosimilars or alternative gene therapies
Key Takeaways
- NDC 45802-0088 corresponds to Zolgensma, a USD 2.1 million gene therapy for SMA.
- The U.S. market estimates over 350 eligible infants annually, with room for growth via early diagnosis.
- Current market revenues forecasted at USD 3-4 billion annually in the near-term.
- Price stability is expected unless policy, competition, or manufacturing cost changes occur.
- Market expansion relies on regulatory approvals for broader patient populations and ongoing payer negotiations.
FAQs
Q1: How does the pricing of Zolgensma compare to other SMA treatments?
A1: It exceeds other treatments significantly; Spinraza costs approximately USD 750,000 annually, while Evrysdi costs about USD 340,000 annually.
Q2: What factors could lead to a price reduction for Zolgensma?
A2: Introduction of biosimilars, negotiations for outcome-based pricing, manufacturing cost reductions, or expanded indications could pressure prices lower.
Q3: Is the market for Zolgensma expected to grow?
A3: Yes, driven by increased newborn screening, early diagnosis, and potential approvals for older patients.
Q4: What are the main barriers to market growth?
A4: High treatment cost, reimbursement hurdles, manufacturing capacity, and competition from alternative therapies.
Q5: How might policy changes affect Zolgensma’s pricing?
A5: Policies promoting price negotiation and cost-containment could lead to reduced reimbursements and lower effective prices.
References
- Food and Drug Administration. (2019). Zolgensma approval letter. FDA.
- EMA. (2020). Zolgensma (onasemnogene abeparvovec). European Medicines Agency.
- Novartis. (2022). Zolgensma pricing and reimbursement. Novartis Reports.
- IQVIA. (2022). Biotech and gene therapy market analysis. IQVIA Reports.
- The SMA Foundation. (2022). Epidemiology and treatment landscape. SMA Foundation.
